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Edited by Jesus AvilaAbstract Tau is the major antigenic component of neuroﬁbril-
lary pathology in tauopathy, including Alzheimers disease.
Although conversion of soluble tau to an insoluble polymerized
ﬁbrillar form is a key factor in the pathogenesis of tauopathy,
the mechanism of the change is unclear and no inhibitors of ﬁbril
formation are available. Monoclonal antibodies against the 1st
or 2nd repeat of the microtubule binding domain, but not the
C-terminal 16 residues, completely inhibited tau aggregation into
PHF. Furthermore, they did not inhibit tau-induced tubulin
assembly. Thus, they are useful to investigate tau protein conver-
sion and will be useful therapeutic lead materials.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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The appearance of insoluble neuroﬁbrillary tangles (NFTs)
in the diseased brain is an important pathological feature of
tauopathy, including Alzheimer disease (AD) [1]. NFTs are
composed of bundles of paired helical ﬁlaments (PHFs), which
are abnormal aggregates of tau protein [2–5]. Tau is one of the
main, although not exclusive, neuronal microtubule-associated
proteins. The most important function of tau is the modula-
tion of microtubule organization during morphogenesis and
process outgrowth in neurons. The discovery of mutations in
the tau gene in familial frontotemporal dementia and parkin-
sonism linked to chromosome 17 (FTDP-17) has provided a
clear link between tau dysfunction and dementing disease [6–
10]. Although the number of NFTs has been reported to beAbbreviations: ThS, thioﬂavin S; AD, Alzheimer disease; NFT, neur-
oﬁbrillary tangle; PHF, paired helical ﬁlament; FTDP-17, frontotem-
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doi:10.1016/j.febslet.2005.01.039correlated with the degree of dementia [11], the direct connec-
tion between NFT formation and neuronal loss causing
dementia is still a matter of debate, and it is important to
understand the mechanism of tau aggregation.
The core of tau aggregation is composed mainly of the
microtubule-binding domain (MBD), which is comprised of
three or four repeats of 31 or 32 amino acids [12], and this do-
main also shows seeding eﬀects on PHF assembly in vitro
[13,14]. Recently, we determined the structure of the 2nd
(2MBD) and 3rd repeat (3MBD) of MBD in water and triﬂuo-
roethanol (TFE) solutions by NMR spectroscopy [14,15]. Both
2MBD and 3MBD showed that the Leu10-Leu-20/Lys20 se-
quence take helical structures with an amphipathic-like distri-
bution of the respective side-chains, whereas the C-terminal
regions are both ﬂexible. On the other hand, at the N-terminal
Val1-Lys6 sequence, 2MBD shows a helical conformation,
whereas 3MBD shows an extended conformation. The amphi-
pathic behavior would be necessary for self-association of
MBD into helical ﬁlaments, because such ﬁlaments are stabi-
lized by the alternating hydrophilic and hydrophobic interac-
tions. The assembly process can be enhanced by the
oxidation of SH groups [13] or polyanions, such as heparin
[16–18].
Although there have been a number of reports concerning
PHF formation [14,19], it remains to be determined how to
prevent self-assembly. Here, we report that RTA-1 and
RTA-2, monoclonal antibodies against ﬁrst or second repeat
of MBD, respectively, but not RTA-C, a monoclonal antibody
against the C-terminal 16 amino acid residues, completely
inhibited in vitro tau aggregation into PHF. Furthermore, they
did not exert any inhibitory eﬀects on tau-induced tubulin
assembly. Thus, RTAs would provide useful tools to investi-
gate the mechanism of the conversion of tau protein from
the soluble to the insoluble state and may also be useful as
therapeutic lead materials.2. Materials and methods
2.1. Production of RTAs
The peptide sequences used as antigens are shown in Fig. 1(a). Pep-
tides were synthesized with additional N-terminal cysteine residues, to
which the carrier protein, keyhole limpet hemocyanin (KLH), was cou-
pled. The Freunds complete and incomplete adjuvant system was used
to inoculate Balb/C mice. Three mice were injected once with completeblished by Elsevier B.V. All rights reserved.
Fig. 1. The peptide sequences of antigens and schematic representation of various tau fragments. (a) A schematic drawing of the longest tau isoform
is shown with the peptide sequences used as antigens. (b) The tau isoform (clone T9) is shown at the top and various tau fragments are aligned below.
1, 2, 3, and 4 indicate 1st (244–274 aa), 2nd (275–305 aa), 3rd (306–336 aa), and 4th (337–368 aa) repeat of MBD, respectively. The numbering of the
aa residues refers to the longest isoform of human tau (441 residues).
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weeks. Seven days after the last injection, spleen cells were harvested
and fused with mouse myeloma cells by standard procedures. Follow-
ing several cycles of cloning and screening by enzyme-linked immuno-
sorbent assay (ELISA), stable hybridoma clones (RTA-1, RTA-2 and
RTA-C) were selected for antibody production. Puriﬁcation of the
antibody was performed as follows. Supernatant of hybridoma culture
was chromatographed sequentially at 4 C on columns of Q-Sepharose
FF (Amersham Biosciences) equilibrated in buﬀer (HEPES–NaOH,
pH 7.0) and Phenyl Toyopearl 650S (Tosoh) equilibrated in buﬀer
(Succinic acid, pH 6.0) and Toyopearl HW-55S (Tosoh) equilibrated
in buﬀer (Tris–HCl, pH 8.0). Protein concentration was monitored
by measuring absorbance at 350 nm. The purity of the antibodies
eluted from the gel ﬁltration column (Toyopearl HW-55S) were
>95% determined by SDS–PAGE followed by CBB staining.2.2. Recombinant proteins, cell lysates and immunoblotting
All tau constructs used in the present study (Fig. 1(b)) were prepared
by polymerase chain reaction ampliﬁcation using a cDNA (clone T9)
encoding the human tau (383 residues) as the template [20]. Schematic
representations of tau fragments are shown in Fig. 1(b). 1MBD,
2MBD, 3MBD and 4MBD indicate the 1st, 2nd, 3rd and 4th repeat
of MBD, respectively. Preparation of recombinant tau proteins
and cell lysates and Western blotting were performed as described in
[21].2.3. In vitro tau aggregation and electron microscopy
Four-repeat MBD (4RMBD) at 15 lM was mixed with 3.8 lM hep-
arin in 50 mM Tris–HCl, pH 7.5, containing 1 mM DTT and incu-
bated at 37 C for 100 min. A 600-mesh copper grid was used for
negative staining electron microscopy. A drop of the protein solution
was placed on the grid along with a drop of 2% uranyl acetate. After
2 min, excess ﬂuid was removed from the grid. Negative-staining elec-
tron microscopy was performed with an electron microscope (Hitachi
H-600) operated at 75 kV.
2.4. Monitoring of PHF formation by ThS ﬂuorescence
Three-repeat MBD (3RMBD), 4RMBD and 4RMBD-C terminal
(4RMBD-Cterm) were adjusted to a concentration of 15 lM using
50 mM Tris–HCl, pH 7.5, containing 10 lM thioﬂavin S (ThS) dye.
Aggregation without or with the indicated RTA (7.5 lM) was induced
by adding heparin (ﬁnal concentration = 3.8 lM) to the reaction solu-
tion and mixed with a pipette prior to ﬂuorescence measurement. The
time scan of the ﬂuorescence intensity was carried out using a JASCO
FP-6500 instrument with a 2-mm quartz cell maintained at 25 C using
a circulating water bath.
2.5. In vitro microtubule assembly assay
Tau-induced tubulin assembly was performed using recombinant
His-tau and bovine brain tubulin (Cytoskeleton) as described in [21].
Brieﬂy, either all or one of His-tau (50 lg, 3.1 lM), tubulin (100 lg,
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added to 400 ll of assembly buﬀer (100 mM PIPES, pH 6.8,
1.25 mM EGTA and 1.25 mM GTP) as indicated and incubated at
37 C. Polymerizations of microtubules at 20 min and 24 h were mon-
itored by measuring absorbance at 350 nm [22,23].Fig. 3. In vitro polymerization of 4RMBD into PHF formation. The
sample was negatively stained with 2% uranyl acetate and analyzed by
electron microscopy. Arrows indicate the typical PHF ultrastructure,
the double-stranded twisted appearance with a crossover repeat of
80 nm. The bar indicates 100 nm.3. Results
3.1. Characterization of RTAs
RTA-1 and RTA-C antibodies bound to both CHO-3Rtau
and CHO-4Rtau (Fig. 2(a)), although RTA-2 bounds to only
CHO-4Rtau. RTA-1 bound speciﬁcally to 1MBD and RTA-
2 to 2MBD (Fig. 2(b)). RTA-1 bound to both 3RMBD and
4RMBD, although RTA-2 bound 4RMBD but not 3RMBD
(Fig. 2(c)). RTA-C did not bind to 1MBD, 2MBD, 3MBD,
4MBD, 3RMBD or 4RMBD.
3.2. MBD aggregation into PHF-like ﬁlaments
It has been reported that the MBD assumes the core struc-
ture of PHF [24] and promotes tau assembly in vitro [13].
We showed recently that 4RMBD aggregates into ﬁlaments
with a typical PHF-like ultrastructure [25]. These ﬁlaments
have a double-stranded twisted appearance with a crossover
repeat of 80 nm (Fig. 3).
3.3. Inhibitory eﬀects of RTAs on PHF formation
Tau aggregation into PHF formation in solution can be
monitored using the reporter dye ThS [26,27]. Both RTA-1
and RTA-2 completely blocked 4RMBD aggregation (Fig.
4(a)). On the other hand, RTA-1 completely blocked 3RMBD
aggregation, while RTA-2 showed only a partial inhibitory ef-Fig. 2. Characterization of RTAs. (a) Aliquots of 10 lg of total cell
lysates from CHO (lane 1), CHO expressing 3Rtau (CHO-3Rtau) (lane
2) and CHO expressing 4Rtau (CHO-4Rtau) (lane 3) were subjected to
SDS–PAGE followed by Western blotting analysis with RTA-1, RTA-
2 and RTA-C. (b) Aliquots of 1 lg of puriﬁed GST-tagged 1MBD
(lane 1), 2MBD (lane 2), 3MBD (lane 3) and 4MBD (lane 4) were
subjected to SDS–PAGE followed by Western blotting analysis with
RTA-1, RTA-2 and RTA-C. (c) Aliquots of 1 lg of puriﬁed His-
tagged 3RMBD (lane 1) and 4RMBD (lane 2) were subjected to SDS–
PAGE followed by Western blotting analysis with RTA-1, RTA-2 and
RTA-C.
Fig. 4. Inhibition of PHF formation by RTA-1 and RTA-2. (a) PHF
formation of 4RMBD in solution was monitored using ThS. RTA-1
and RTA-2 completely inhibited 4RMBD aggregation into PHF. (b)
PHF formation of 3RMBD in solution was monitored using ThS.
RTA-1 completely, while RTA-2 partially inhibited 3RMBD aggre-
gation into PHF.fect (Fig. 4(b)), indicating that the striking inhibitory eﬀects of
RTA-1 and RTA-2 were dependent on binding to MBD.
3.4. Inhibitory eﬀects of RTAs are dependent on binding to
MBD
Next, we examined whether the inhibitory eﬀects of RTAs
were dependent on binding to MBD or whether any antibodies
capable of binding to regions of tau other than MBD could
also inhibit PHF formation. In this experiment, we used
MBD-Cterm, because it also aggregated into ﬁlaments and
formed PHF (Fig. 5, line RTA()). RTA-C detected the C-ter-
Fig. 5. The inhibitory eﬀects of RTAs depend on binding to MBD.
PHF formation of MBD-Cterm was monitored using ThS. RTA-1 and
RTA-2 completely, while RTA-C partially inhibited 4RMBD-Cterm
aggregation into PHF.
Fig. 6. Eﬀects of RTAs on tau-induced tubulin assembly. Tau-induced
tubulin assembly was analyzed with or without one of the RTAs.
Polymerization of microtubules was monitored by measuring the
absorbance at 350 nm. RTA-1, RTA-2 and RTA-C did not inhibit tau-
induced tubulin assembly, but RTA-1 and RTA-2 promoted tau-
induced tubulin assembly.
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showed a partial inhibitory eﬀect, although RTA-1 and
RTA-2 completely blocked MBD-Cterm aggregation as mon-
itored using ThS (Fig. 5). These observations further sup-
ported the conclusion that the striking inhibitory eﬀects of
RTAs were dependent on binding to MBD.
3.5. RTAs did not inhibit tau-induced tubulin assembly
Tau is a microtubule-associated protein (MAP) and is in-
volved in the promotion of tubulin assembly into microtubules
and their stabilization. As expected, when recombinant His-
tau was co-incubated with tubulin, it induced tubulin assem-
bly. To examine the eﬀects of RTAs on the tau-induced tubulin
assembly, we added each RTA to the reaction. RTAs did not
exert any inhibitory eﬀects on the tau-induced tubulin assem-
bly (Fig. 6). Interestingly, RTA-1 and RTA-2, but not RTA-
C, promoted tau-induced tubulin assembly.4. Discussion
AD and some other dementing diseases, collectively known
as tauopathies, are characterized by abnormal protein depositsin the brain. They are formed by ﬁbrous assemblies called
PHFs, which consist of tau protein. In the adult human brain,
six tau isoforms are expressed by alternative splicing from a
single gene located on chromosome 17. They diﬀer in the pres-
ence of three or four repeats of MBD in conjunction with 0-,
29-, and 58-amino acid inserts located in the amino-terminal
region.
Mutations in the tau gene directly cause neurodegeneration
in FTDP-17, demonstrating that abnormalities of tau can be
an important part of the neurodegenerative process [6–10].
The major categories of functional defects caused by tau muta-
tions are decreased microtubule binding, increased propensity
for self-polymerization, increased hydrophobicity, structural
modiﬁcations, and altered isoform ratios [28]. Most mutations
lie within MBD and those outside MBD are very close to
MBD or lie in regions known to interact with MBD. Intronic
mutations alter isoform expression of three-repeat versus four-
repeat tau. All mutations found to date have some relevance to
MBD [28].
MBD is composed of three or four microtubule-binding re-
peat containing a highly conserved repeat region of 18 amino
acids that is known to interact with microtubules and less
well-conserved 13–14 amino acid interrepeat regions that also
interact with microtubules and greatly inﬂuence tau binding
[29]. There is accumulating evidence that MBD would be vital
to the polymerization of tau. Polyanions, such as heparin, can
induce MBD polymerization. The resulting ﬁlaments have the
morphological characteristics of PHFs, twisting with a regular
periodicity of approximately 80 nm (Fig. 3) [25]. The 306-VQI-
VYK-311 residues in the third microtubule-binding repeat are
required for the induction of tau polymerization [30]. The
stretch has been shown to form a b-strand structure in hydro-
phobic environments in vitro [14]. This b-strand probably rep-
resents the minimum unit required for tau–tau interactions, as
a peptide composed of repeats of this sequence was demon-
strated to be capable of self-polymerization [30]. Recently,
we showed that phosphorylation of serine residues in MBD
by PKN reduces the ability of tau to bind to tubulin or to sta-
bilize microtubule organization [21]. Furthermore, phosphory-
lation in or near MBD protects tau aggregation into ﬁlaments
[31] and reduces some proline-directed phosphorylation, one
of the hallmarks observed in the brain of AD patients
[21,32,33]. These ﬁndings further conﬁrmed that MBD plays
important roles in the pathogenesis of tauopathy.
In the present study, we showed that RTA-1 and RTA-2,
which bind the 1st repeat and 2nd repeat of MBD, respec-
tively, completely blocked 4RMBD and 4RMBD-Cterm
aggregation into ﬁlaments (Figs. 4 and 5), but RTA-2 and
RTA-C partially inhibited 3RMBD and 4RMBD-Cterm
aggregation, respectively. Our ﬁndings indicate that when the
antibody (RTA-1 and -2) binds to MBD, it completely blocks
tau aggregation, although any antibody to tau would have
some partial inhibitory eﬀect on aggregation. The partial
inhibitory eﬀects of antibodies seem to be independent of their
binding to tau, as RTA-2, which did not bind to 3RMBD, still
showed a partial inhibitory eﬀect on 3RMBD aggregation
(Fig. 4(b)), and RTA-C also showed an inhibitory eﬀect on
3RMBD and 4RMBD aggregation to the same extent as
RTA-2 on 3RMBD aggregation (data not shown). MBD has
been shown to assume an a-helical structure with amphipathic
behavior [14,15], which would be necessary for self-association
of MBD into helical ﬁlaments, because such ﬁlaments are sta-
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tions. The Fc portion of an antibody is very hydrophobic and
may inhibit the stabilization reaction by disturbing hydropho-
bic interactions of MBD. On the other hand, the Fc portion
may promote microtubule assembly [34]. It should be empha-
sized that RTA-1 and RTA-2, but not RTA-C, increased the
ability of tau to promote microtubule assembly rather than
interrupting the interaction of tau with tubulin, indicating that
they reduce the pathological eﬀects but augment the physiolog-
ical function of tau.
Protein–protein interactions have a key role in most biolog-
ical processes, both physiological and pathological, and oﬀer
attractive opportunities for therapeutic intervention. However,
the development of antagonists that modulate protein–protein
interactions is diﬃcult due to issues such as the lack of well-
deﬁned binding pockets. Here, we conﬁrmed that MBD is a
key binding domain of tau–tau interaction involved in PHF
formation and we also showed that RTAs completely inhibit
tau aggregation. Thus, RTAs may provide useful tools for
therapeutic intervention.
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